ANALYSIS BY CANCER INDICATION

 

 

Epic Sciences’ platform technology has been used in studies on various stages of disease progression across a number of different indications, including prostate, breast and lung cancer.

Current studies in metastatic breast cancer have shown links between genotypic heterogeneity and specific phenotypic profiles.  This flexible starting sample has also enabled the demonstration of feasibility in melanoma, pancreatic, ovarian, colorectal, and bladder cancers. 

 Extensive single cell phenotypic and genomic profiling of CTCs from a patient identified the co-occurrence of AR+, ER+ and HER2+ CTCs as well as cellular genomic heterogeneity. Key genomic alterations linked to phenotype were observed.

To date, Epic Sciences has identified the co-occurrence of AR+, ER+ and HER2+ CTCs and cellular genomic heterogeneity through extensive single cell phenotypic and genomic profiling of CTCs. We have also observed key genomic alterations that are linked to phenotype.

To learn more about Epic Sciences’ work in your area of interest, download our posters for:

Breast cancer studies

Prostate cancer studies

Lung cancer studies

Bladder cancer studies

Interested in joining the team? Review our open positions here